NCT04685616 · University College, London
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
(RADAR)
What this study is about
RADAR is a multicentre, international, randomised, where both patients and doctors know the treatment given phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New Zealand.
View original scientific description
RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New Zealand. Trial 2 will be led by the Canadian Cancer Trials Group (CCTG) and conducted in North America, with CCTG the regulatory sponsor in Canada, and University of Miami the regulatory sponsor and IND holder in the US.
Interventions
RADIATION
Involved site radiotherapy
Involved site radiotherapy as per International Lymphoma Radiation Oncology Group (ILROG) guidelines. Recommended dose 30Gy
DRUG
Doxorubicin
See arm description
DRUG
Bleomycin
See arm description
DRUG
Brentuximab vedotin
See arm description
DRUG
Vinblastine
See arm description
DRUG
Dacarbazine
See arm description
DRUG
Haematopoietic growth factor
See arm description
Primary outcome measures
Progression free survival (PFS)
Time frame: 3 years from end of treatment
Time from randomisation to first date of progression or death
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Males and females aged 16-69 years (inclusive) (age range is 18-69 in US and EU)
- Histologically confirmed classical Hodgkin lymphoma
- Stage I or II supradiaphragmatic disease with no mediastinal bulk disease (defined as greater than a third of the transthoracic diameter at any level of thoracic vertebra as determined by CT) or B symptoms. Bulky disease at other sites is acceptable. Extranodal disease (single extranodal site (stage I) or contiguous nodal extension (stage II)) is acceptable.
- ECOG performance status 0-2.
- No previous treatment for Hodgkin lymphoma
- Fit to receive anthracycline-based chemotherapy (patients with a history of ischaemic heart disease or hypertension should have a left ventricular ejection fraction of ≥50%)
- Creatinine clearance (measured or calculated \>40ml/min
- Total bilirubin \<1.5 x upper limit of normal, unless attributable to disease or known Gilbert's syndrome
- ALT or AST \< 2 x upper limit of normal
- Adequate bone mar
Where
- Stanford, California
- Miami, Florida
- New York, New York
Collaborators
Takeda, University of Miami, European Organisation for Research and Treatment of Cancer - EORTC, Australasian Leukaemia and Lymphoma Group, Seagen Inc., Canadian Cancer Trials Group
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Jul 8, 2026 · Source of record for eligibility and locations